Altre lingue Asarina Pharma AB

Azioni

ASAP

SE0011641794

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 12:47:54 30/04/2024			Variaz. 5gg	Var. 1 gen.
0,968 ^SEK	-1,22%		+7,56%	+10,00%

27/02	Asarina Pharma AB (publ) riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI
2023	Asarina Pharma AB (publ) riporta i risultati degli utili per il semestre chiuso al 30 giugno 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023	27/02
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB	30/11
Asarina Pharma updates on partnering and financials	16/11
Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)	23/08/23
Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	23/08/23
ASARINA PHARMA - POSITIVE TOURETTE SYNDROME RESULTS TO BE PRESENTED AT ESSTS, 15TH EUROPEAN CONFERENCE ON TOURETTE SYNDROME AND TIC DISORDERS	24/05/23
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)	22/05/23
Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	08/05/23
Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	05/05/23
Asarina Pharma's Positive Phase IIa Tourette Syndrome Results to Be Presented At Ticcon, the Virtual National Conference of the Tourette Association of America	05/05/23
Asarina Pharma AB (publ) releases Annual Report 2022	01/05/23
Asarina Pharma AB (publ) releases Annual Report 2022	28/04/23
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)	18/04/23
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette syndrome	03/04/23
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome	01/04/23
Asarina Pharma AB (publ) releases Year-End Report 2022	27/02/23
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23
Last Patient Last Visit for landmark Tourette Syndrome study	02/02/23
Asarina Pharma - Patient recruitment completed in landmark Tourette syndrome study	17/10/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Asarina Pharma AB

Azioni

ASAP

SE0011641794

Altre lingue

Filtri